Tirzepatide is a novel peptide that has shown to be highly effective for in preclinical studies. In a study published in the journal Obesity, tirzepatide was found to reduce by up to 13% and by up to 19% in rats when compared to placebo. The study authors concluded that tirzepatide could be a promising new therapy for the treatment of obesity.

Tirzepatide works by mimicking the effects of the hormone GLP-1, which is known to promote satiety and weight loss. GLP-1 is released in response to food intake and signals the brain to reduce hunger and promote fullness. Tirzepatide is thought to be more effective than other GLP-1 mimetics because it is more resistant to degradation by enzymes in the gut.

In addition to its effects on body weight, tirzepatide has also been shown to improve glucose tolerance and reduce blood pressure in preclinical studies. These effects are likely due to the ability of tirzepatide to stimulate insulin release from the pancreas.

Tirzepatide is currently being evaluated in a Phase 2 clinical trial in obese and patients. The results of this trial are expected to be announced in 2019.

If tirzepatide is found to be safe and effective in humans, it could become a valuable new tool in the fight against obesity.